Product Name:(R)-2-tert-Butyl 8a-methyl 6-oxo-3,4,6,7,8,8a-hexahydroisoquinoline-2,8a(1H)-dicarboxylate

IUPAC Name:2-tert-butyl 8a-methyl (8aR)-6-oxo-1,2,3,4,6,7,8,8a-octahydroisoquinoline-2,8a-dicarboxylate

CAS:445312-74-3
Molecular Formula:C16H23NO5
Purity:97%
Catalog Number:CM229457
Molecular Weight:309.36

Packing Unit Available Stock Price($) Quantity
CM229457-10g in stock ǪľȃŤ

For R&D use only.

Inquiry Form

   refresh    

Product Details

CAS NO:445312-74-3
Molecular Formula:C16H23NO5
Melting Point:-
Smiles Code:O=C(N(CCC1=C2)C[C@@]1(C(OC)=O)CCC2=O)OC(C)(C)C
Density:
Catalog Number:CM229457
Molecular Weight:309.36
Boiling Point:
MDL No:
Storage:

Column Infos

Relacorilant
Corcept completes enrollment in phase 3 Gradient trial of Relacorilant in patients with Adrenal Cushing’s Syndrome. Cushing's disease or hypercortisolism is a rare endocrine disorder that occurs when a pituitary adenoma makes excessive cortisol. Cortisol exerts its functions by binding to the glucocorticoid receptor (GR).
Relacorilant is a selective glucocorticoid receptor modulator (SGRM) in clinical development to prevent the effects of high cortisol. Relacorilant is being studied in various serious disorders, including ovarian, adrenal and prostate cancer and Cushing’s syndrome.